Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 May 2017 17:33

RNS Number : 5192E
Verona Pharma PLC
08 May 2017
 

 

 

 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: 

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: 

Growth Equity Opportunities IV, LLC

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

May 2, 2017

6. Date on which issuer notified:

May 5, 2017

7. Threshold(s) that is/are crossed orreached: 

8% to 9% change at direct interest level

     
 

 

8. Notified details:

A: Voting rights attached to shares 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights 

Direct

Direct 

Indirect 

Direct

Indirect

Ordinary Shares

 

GB00B06GSH43

4,424,065

4,424,065

4,424,065

4,424,065

 

4.47%

 

 

US9250501064

 

 

5,333,328

5,333,328

 

5.39%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate 

Exercise/Conversion Period 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instrument

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date 

Exercise/Conversion period 

Number of voting rights instrument refers to

 

% of voting rights 

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

9,757,393

9.86%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: 

 

Growth Equity Opportunities IV, LLC is a limited liability company formed in the State of Delaware, United States

New Enterprise Associates 15, L.P., a limited partnership formed in the State of Delaware, is its sole member

NEA Partners 15, L.P., a limited partnership formed in the State of Delaware, is its general partner

NEA 15 GP, LLC, a limited liability company formed in the State of Delaware, is its general partner

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

Figures are based on a total number of 99,014,164 Ordinary Shares outstanding, as per the Company's Announcement of May 2, 2017.

14. Contact name:

Louis Citron, New Enterprise Associates

15. Contact telephone number:

+1 (410) 842-4000

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUBPAUPMGQR
Date   Source Headline
5th Jan 201210:42 amPRNResult of General Meeting
8th Dec 20112:05 pmPRNCompletion of GBP3.25 million placing
25th Nov 20113:55 pmPRNHolding(s) in Verona Pharma
10th Nov 20117:00 amPRNPositive results for COPD pilot study
3rd Nov 20117:00 amPRNWH Ireland Limited appointed as Nomad and Broker
20th Sep 20117:00 amPRNIssue of Options
7th Sep 20117:01 amPRNInterim Report for the six months ended 30 June 2011
7th Sep 20117:00 amPRNVRP700 demonstrates significant anti-tussive effects
17th Aug 20117:22 amPRNBronchodilation in asthmatics maintained with RPL554
7th Jun 20114:21 pmPRNDirector Options
3rd Jun 20113:43 pmPRNResult of AGM
3rd Jun 201111:09 amPRNAGM Statement
12th May 20117:00 amPRNStart of New Phase II Clinical Trial of RPL554
9th May 20115:29 pmPRNCorrection of AGM date
9th May 20114:13 pmPRNNotice of AGM and Issue of Annual Report
21st Apr 20117:00 amPRNAppointment of Joint Broker
12th Apr 20117:00 amPRNFirst COPD Trial with RPL554 Begins in Rome
23rd Mar 20117:00 amPRNPreliminary Unaudited Results
1st Mar 201110:24 amPRNTotal Voting Rights
22nd Feb 20111:24 pmPRNIssue of Equity
22nd Feb 20117:02 amPRNVerona Pharma announces positive results for RPL554
7th Jan 20117:00 amPRNResponse to Share Price Movement
26th Nov 20107:01 amPRNRPL554: PoC studies on industry-standard inhaler devices
26th Nov 20107:00 amPRNNew Higher Dose RPL554 Clinical Trial in Asthma
27th Oct 20107:00 amPRNVRP700 for chronic cough enters clinic
6th Sep 20107:00 amPRNHalf-yearly Report
27th Aug 20107:00 amPRNNotice of Interim Results
28th Jun 20107:00 amPRNUpdate on RPL554 and Cough Projects
18th Jun 20104:55 pmPRNGrant of Options
3rd Jun 201012:57 pmPRNResult of AGM
3rd Jun 20107:00 amPRNAGM Statement
4th May 20103:56 pmPRNNotice of AGM
26th Mar 20107:00 amPRNPreliminary Results
20th Jan 20103:52 pmPRNNotice of Interest
14th Jan 20107:00 amPRNNew Year Progress Report
7th Jan 20107:00 amPRNNotice of Interest
6th Jan 201010:37 amPRNApplication for admission of new Ordinary Shares
24th Dec 20099:13 amPRNRESULT OF GENERAL MEETING
18th Dec 20094:16 pmPRNApplication for Admission of New Ordinary Shares
15th Dec 20098:12 amPRNDirectors' Shareholding
9th Dec 20098:04 amPRNPosting of Circular
28th Oct 200911:26 amPRNNotice of interest
11th Sep 20094:57 pmPRNFurther re Board Appointment
11th Sep 20097:03 amPRNBoard Appointment
11th Sep 20097:00 amPRNRPL554 proven safe and effective in patients with asthma
4th Sep 20097:00 amPRNHalf-yearly Report
2nd Sep 20097:00 amPRNChange of Nomad
29th May 20097:00 amPRNTotal Voting Rights
22nd May 200912:01 pmPRNResult of AGM
20th May 20097:00 amPRNClinical Trial Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.